非维生素K拮抗剂口服抗凝药与维生素K拮抗剂相关脑出血患者院内死亡率的关联
该回顾性队列研究纳入2013年10月至2016年12月1662家Get With The Guidelines-Stroke医院收治的141311例脑出血患者,评估既往7天内口服抗凝药使用与院内死亡率的关系。结果显示,与未使用口服抗凝药者相比,华法林者院内死亡率更高(ARD 9.0%,AOR 1.62),NOAC者亦更高(ARD 3.3%,AOR 1.21);但与华法林者相比,NOAC者院内死亡率更低(ARD -5.7%,AOR 0.75)。提示脑出血后抗凝药物类型与预后相关。
要点
- 与未使用口服抗凝药者相比,既往使用华法林者院内死亡率更高(ARD 9.0%,AOR 1.62,97.5%CI 1.53-1.71)。
- 与未使用口服抗凝药者相比,既往使用NOAC者院内死亡率亦更高(ARD 3.3%,AOR 1.21,97.5%CI 1.11-1.32)。
- 与既往使用华法林者相比,既往使用NOAC者院内死亡率更低(ARD -5.7%,AOR 0.75,97.5%CI 0.69-0.81)。
- 三组急性脑出血卒中严重程度(NIHSS)无显著差异(中位数:华法林9,NOAC 8,无OAC 8)。
- 双重抗血小板治疗者中NOAC与华法林死亡率差异更大(32.7% vs 47.1%,ARD -15.0%),但交互作用P=0.07未达统计学显著。
适用人群与场景
- 2013年10月至2016年12月期间,1662家Get With The Guidelines-Stroke医院收治的141311例脑出血患者。
- 既往口服抗凝药使用定义为入院前7天内任何口服抗凝药使用。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量141311例;1662家Get With The Guidelines-Stroke医院;人群为脑出血患者。
- 暴露:既往口服抗凝药使用(华法林、NOAC、未使用口服抗凝药),定义为入院前7天内任何口服抗凝药使用。
- 主要终点:院内死亡率。未调整院内死亡率:华法林32.6%,NOAC 26.5%,未使用口服抗凝药22.5%。
- 与未使用口服抗凝药者相比,华法林者院内死亡率更高(ARD 9.0%,97.5%CI 7.9%-10.1%;AOR 1.62,97.5%CI 1.53-1.71)。
- 与未使用口服抗凝药者相比,NOAC者院内死亡率更高(ARD 3.3%,97.5%CI 1.7%-4.8%;AOR 1.21,97.5%CI 1.11-1.32)。
- 与华法林者相比,NOAC者院内死亡率更低(ARD -5.7%,97.5%CI -7.3%至-4.2%;AOR 0.75,97.5%CI 0.69-0.81)。
- 双重抗血小板治疗者中,NOAC者与华法林者院内死亡率分别为32.7% vs 47.1%(ARD -15.0%,95.5%CI -26.3%至-3.8%;AOR 0.50,97.5%CI 0.29-0.86);无抗血小板治疗者中分别为26.4% vs 31.7%(ARD -5.0%,97.5%CI -6.8%至-3.2%;AOR 0.77,97.5%CI 0.70-0.85);交互作用P=0.07,未达统计学显著。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脑出血患者,应询问入院前7天内是否使用口服抗凝药,既往使用NOAC或华法林者院内死亡风险均高于未使用者。
- 既往使用NOAC的脑出血患者,其院内死亡风险低于既往使用华法林者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH).
OBJECTIVE: To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among patients with ICH.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 141 311 patients with ICH admitted from October 2013 to December 2016 to 1662 Get With The Guidelines-Stroke hospitals.
EXPOSURES: Anticoagulation therapy before ICH, defined as any use of OACs within 7 days prior to hospital arrival.
MAIN OUTCOMES AND MEASURES: In-hospital mortality.
RESULTS: Among 141 311 patients with ICH (mean [SD] age, 68.3 [15.3] years; 48.1% women), 15 036 (10.6%) were taking warfarin and 4918 (3.5%) were taking NOACs preceding ICH, and 39 585 (28.0%) and 5783 (4.1%) were taking concomitant single and dual antiplatelet agents, respectively. Patients with prior use of warfarin or NOACs were older and had higher prevalence of atrial fibrillation and prior stroke. Acute ICH stroke severity (measured by the National Institutes of Health Stroke Scale) was not significantly different across the 3 groups (median, 9 [interquartile range, 2-21] for warfarin, 8 [2-20] for NOACs, and 8 [2-19] for no OACs). The unadjusted in-hospital mortality rates were 32.6% for warfarin, 26.5% for NOACs, and 22.5% for no OACs. Compared with patients without prior use of OACs, the risk of in-hospital mortality was higher among patients with prior use of warfarin (adjusted risk difference [ARD], 9.0% [97.5% CI, 7.9% to 10.1%]; adjusted odds ratio [AOR], 1.62 [97.5% CI, 1.53 to 1.71]) and higher among patients with prior use of NOACs (ARD, 3.3% [97.5% CI, 1.7% to 4.8%]; AOR, 1.21 [97.5% CI, 1.11-1.32]). Compared with patients with prior use of warfarin, patients with prior use of NOACs had a lower risk of in-hospital mortality (ARD, -5.7% [97.5% CI, -7.3% to -4.2%]; AOR, 0.75 [97.5% CI, 0.69 to 0.81]). The difference in mortality between NOAC-treated patients and warfarin-treated patients was numerically greater among patients with prior use of dual antiplatelet agents (32.7% vs 47.1%; ARD, -15.0% [95.5% CI, -26.3% to -3.8%]; AOR, 0.50 [97.5% CI, 0.29 to 0.86]) than among those taking these agents without prior antiplatelet therapy (26.4% vs 31.7%; ARD, -5.0% [97.5% CI, -6.8% to -3.2%]; AOR, 0.77 [97.5% CI, 0.70 to 0.85]), although the interaction P value (.07) was not statistically significant.
CONCLUSIONS AND RELEVANCE: Among patients with ICH, prior use of NOACs or warfarin was associated with higher in-hospital mortality compared with no OACs. Prior use of NOACs, compared with prior use of warfarin, was associated with lower risk of in-hospital mortality.
参考来源
- Inohara T, Xian Y, Liang L, et al. Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA. 2018. PMID: 29372247. doi:10.1001/jama.2017.21917
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。